2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Huppert L, Wolf D, Yau C, Brown-Swigart L, Hirst G, Isaacs C, Pusztai L, Pohlmann P, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer L, Esserman L, Rugo H. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals Of Oncology 2024 PMID: 39477071, DOI: 10.1016/j.annonc.2024.10.018.Peer-Reviewed Original ResearchDistant recurrence-free survivalEarly-stage breast cancerPathological complete responsePathologic complete response rateClinical/molecular featuresComplete responseER-positiveBreast cancerRate of pathological complete responseResponse to neoadjuvant chemotherapyRecurrence-free survivalI-SPY2 trialOptimal treatment selectionNeoadjuvant armER/PR statusLobular histologyNeoadjuvant chemotherapyIII diseaseImmune signaturesNegative diseaseOptimal therapyI-SPY2Excellent outcomesTreatment armsFollow-up
2022
Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
Huppert L, Rugo H, Pusztai L, Mukhtar R, Chien A, Yau C, Wolf D, Berry D, van 't Veer L, Yee D, DeMichele A, Esserman L, Consortium I. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. Journal Of Clinical Oncology 2022, 40: 504-504. DOI: 10.1200/jco.2022.40.16_suppl.504.Peer-Reviewed Original ResearchI-SPY2 trialInvestigational agentsMolecular subtypesNodal statusPathologic complete response rateMultiple investigational agentsComplete response ratePhase 3 trialHER2- breast cancerLuminal statusNeoadjuvant therapyPrimary endpointImmune signaturesPCR rateTreatment armsHeterogenous diseaseBC therapySubtype 5Breast cancerImmune biologyResponse ratePembrolizumabHormone receptorsDiseaseTrials
2017
Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races.
Szekely B, Safonov A, Karn T, Bhagwagar S, Killelea B, Silber A, Hatzis C, Pusztai L. Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races. Journal Of Clinical Oncology 2017, 35: e13028-e13028. DOI: 10.1200/jco.2017.35.15_suppl.e13028.Peer-Reviewed Original ResearchTriple-negative breast cancerNon-AA patientsImmune microenvironmentAfrican American womenImmune signaturesNeoantigen loadImmune metagenesLower pathologic complete response (pCR) ratesPathologic complete response rateComplete response rateNegative breast cancerAmerican womenMann-Whitney U testSignificant differencesClonal heterogeneityTCGA data setsDeletion loadNeoadjuvant therapyLymphocyte countTIL countAA patientsOverall mutational loadHistologic tumorsBreast cancerTreatment response
2012
172O ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups
Iwamoto T, Pusztai L, Matsuoka J, Callari M, Kelly C, Qi Y, Motoki T, Taira N, Santarpia L, Doihara H, Gianni L, Bianchini G. 172O ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups. Annals Of Oncology 2012, 23: ix74-ix75. DOI: 10.1016/s0923-7534(20)32783-6.Peer-Reviewed Original ResearchPathologic complete responseER statusResidual diseaseER-/HER2HER2 cancersBetter prognosisBreast cancerHER2-positive breast cancerImmune gene signaturesSystemic adjuvant therapyPositive breast cancerEstrogen receptor statusHigher chemotherapy sensitivityDistinct molecular subtypesNeoadjuvant taxaneAdjuvant therapyImmune signaturesComplete responseReceptor statusHER2 patientsPoor prognosisMolecular subtypesChemotherapy sensitivityPredictive valueHER2